GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptinyx Inc (OTCPK:APTX) » Definitions » Change In Prepaid Assets

Aptinyx (Aptinyx) Change In Prepaid Assets : $-2.48 Mil (TTM As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aptinyx Change In Prepaid Assets?

Aptinyx's Change In Prepaid Assets for the quarter that ended in Mar. 2023 was $1.20 Mil. It means Aptinyx's Prepaid Assets increased by $1.20 Mil from Dec. 2022 to Mar. 2023 .

Aptinyx's Change In Prepaid Assets for the fiscal year that ended in Dec. 2022 was $-1.31 Mil. It means Aptinyx's Prepaid Assets declined by $1.31 Mil from Dec. 2021 to Dec. 2022 .


Aptinyx Change In Prepaid Assets Historical Data

The historical data trend for Aptinyx's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptinyx Change In Prepaid Assets Chart

Aptinyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Prepaid Assets
Get a 7-Day Free Trial -0.26 -3.17 -2.56 -0.30 -1.31

Aptinyx Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 -0.49 -2.64 -0.56 1.20

Aptinyx Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptinyx Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Aptinyx's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptinyx (Aptinyx) Business Description

Traded in Other Exchanges
N/A
Address
909 Davis Street, Suite 600, Evanston, IL, USA, 60201
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Executives
Joan W. Miller director C/O APTINYX INC., 909 DAVIS ST., SUITE 600, EVANSTON IL 60201
Norbert G Riedel director, officer: CEO and President BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Ashish Khanna officer: CFO and CBO 909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Rachel E. Sherman director 909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Partners, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Jeffrey Lawrence Schwartz 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Bcip Life Sciences Associates, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

Aptinyx (Aptinyx) Headlines

From GuruFocus

Aptinyx Announces Formation of Scientific Advisory Board

By Business Wire Business Wire 02-03-2022

Aptinyx to Present at the SVB Securities Global Biopharma Conference

By Business Wire Business Wire 01-31-2023